Partnerships

Our connections enable you to shape a project to your needs, and only work with best-in-class solutions.

We have a singular focus at evitria – transient antibody expression in CHO. However, we work with a network of trusted partners, each with specific expertise. Whatever the shape of your project, evitria can support you.

LET’S GET IN TOUCH

Our expert network

Our connections enable you to shape a project to your needs, and only work with best-in-class solutions

If you are a service provider or technology licensor interested in partnering with evitria to enhance antibody development workflows, please get in touch with our business development team to explore how we can work with you in the future.

BECOME PART OF OUR NETWORK

Therapeutic workflow

Screening & lead selection

Transient expression

Characterization

CMC

Selected partners

Atlas Antibodies

As part of Atlas Antibodies, evitria gains access to expanded resources and expertise, delivering even greater value to researchers. This collaboration combines Atlas Antibodies’ deep experience in producing highly validated research antibodies with evitria’s proficiency in custom recombinant antibody expression.

Atlas Antibodies partners with evitria to support rapid R&D screening and selection through their extensive catalog of over 25,000 antibody constructs covering the human proteome. Their highly characterized and validated mono- and polyclonal antibodies provide researchers with reliable, off-the-shelf solutions for efficient research and development.

Lonza

Lonza is a leading company with expertise in fields like small molecules, biologics, and CGTs. Supporting services for both GMP and non-GMP applications, Lonza is a sought-after partner both in clinical and production settings, with several innovative techniques in their portfolio.

With Lonza’s bYlok® bispecific pairing technology, for instance, it is possible to considerably increase efficiency in the production of bispecific antibodies – tools that are gaining more and more attention in biomedical and biopharmaceutical research.

Rapid Novor

Rapid Novor helps researchers decode immunity so they can rapidly and effortlessly develop diagnostics, therapies, reagents, and treatments. Through antibody discovery and antibody sequencing services.

Rapid Novor have empowered thousands of researchers. The innovative next generation protein sequencing technology they have developed has the potential to unlock countless discoveries for human health. Their technology relies on mass spectrometry and advanced bioinformatics that delivers the correct sequence every time – this means you can confidently sequence and recombinantly express mAbs starting only with a small sample of protein from any species.

ProBioGen

ProBioGen is a renowned, Berlin-based Contract Development and Manufacturing Organization (CDMO), which operates on an international scale. They offer proprietary innovative technologies for optimized biopharmaceutical manufacturing and analysis.

ProBioGen’s service focus is on cell line engineering, process development, and GMP manufacturing of biopharmaceutical active ingredients and vaccines for clients in biotech and pharma. ProBioGen has been operational for more than 25 years.

RoukenBio

RoukenBio partners with biotherapeutic innovators worldwide, offering in vitro drug discovery services across human immunology, bioanalytical methods, cell line engineering, and bioassay development. They support research from early discovery to GMP-ready potency assays, focusing on areas like immuno-oncology and inflammation. RoukenBio also develops custom solutions, including their IndEx-2 inducible cell line platform, to replicate disease states and advance therapeutic projects.

As a partner of evitria, RoukenBio offers comprehensive antibody characterization services, from antigen binding studies to functional assays. They provide SPR assessments to measure binding affinities and kinetics, as well as cell-based assays to evaluate antibody effector functions. RoukenBio also specializes in custom solutions for complex antibodies, such as bispecifics, multi-specifics, and checkpoint inhibitors, helping to advance innovative therapeutic development.